Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma.
Published: 26th July 2017
Authors: A. Cucchetti, V. Mazzaferro, A. D. Pinna, C. Sposito, R. Golfieri, C. Serra et al.
When comparing the efficacy of surgical and non‐surgical therapies for hepatocellular carcinoma (HCC), a major limitation is the causal inference problem. This concerns the impossibility of seeing both outcomes of two different treatments for the same individual at the same time because one is inevitably missing. This aspect can be addressed methodologically by estimating the so‐called average treatment effect (ATE).
To estimate the ATE of hepatic resection over locoregional therapies for HCC, data from patients treated in two tertiary care settings between August 2000 and December 2014 were used to obtain counterfactual outcomes using an inverse probability weight survival adjustment.
A total of 1585 patients were enrolled: 815 underwent hepatic resection, 337 radiofrequency ablation (RFA) and 433 transarterial chemoembolization (TACE). The option of operating on all patients who had tumour ablation returned an ATE of +9·8 months for resection (effect size 0·111; adjusted
ATE estimation suggests that hepatic resection is a better treatment option than ablation and TACE in patients with HCC.Read more
You may also be interested in
Authors: R. Green, S. C. Charman, T. Palser
Notes: Variation in compliance related to outcomes
Authors: T. Maeta, T. Ebata, E. Hayashi, T. Kawahara, S. Mizuno, N. Matsumoto et al.
Notes: Poor survival despite portal vein resection
Meta‐analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma.
Authors: S. Erridge, P. H. Pucher, S. R. Markar, G. Malietzis, T. Athanasiou, A. Darzi et al.
Notes: No evidence for best treatment
Meta‐analysis of single‐port versus conventional laparoscopic cholecystectomy comparing body image and cosmesis. BJS 2017; 104: 1141-1159.
Authors: R. Haueter, T. Schütz, D. A. Raptis, P.‐A. Clavien, M. Zuber
Notes: Single port superior for cosmesis, body image and pain
Systematic review of the influence of chemotherapy‐associated liver injury on outcome after partial hepatectomy for colorectal liver metastases.
Authors: J. Zhao, K. M. C. van Mierlo, J. Gómez‐Ramírez, H. Kim, C. H. C. Pilgrim, P. Pessaux et al.
Notes: Increased complications in severe SD and steatohepatitis
Authors: R. Ahola, A. Siiki, K. Vasama, M. Vornanen, J. Sand, J. Laukkarinen et al.
Notes: Centralization influences long‐term survival
Systematic review of transarterial embolization for hepatocellular adenomas. BJS 2017; 104: 823-835.
Authors: B. V. van Rosmalen, R. J. S. Coelen, M. Bieze, O. M. van Delden, J. Verheij, C. H. C. Dejong et al.
Notes: Safe alternative to surgery
Meta‐analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. BJS 2017; 104: 814-822.
Authors: A. Acharya, S. R. Markar, M. H. Sodergren, G. Malietzis, A. Darzi, T. Athanasiou et al.
Notes: No benefit
Authors: T. Ebata, T. Mizuno, Y. Yokoyama, T. Igami, G. Sugawara, M. Nagino et al.
Notes: irresectability revisited
Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Notes: Selected patients benefit
Accuracy of circulating histones in predicting persistent organ failure and mortality in patients with acute pancreatitis. BJS 2017; 104: 1215-1225.
Authors: T. Liu, W. Huang, P. Szatmary, S. T. Abrams, Y. Alhamdi, Z. Lin et al.
Notes: Potential as early biomarker